Marco Colonna and his team have made significant strides in developing a novel approach to Alzheimer’s disease through engineered astrocytes. Their research focuses on creating Aβ-specific chimeric antigen receptor (CAR) constructs that leverage the phagocytic capabilities of astrocytes, shifting the paradigm from traditional monoclonal antibody therapies. This transition was prompted by the technical limitations associated with existing monoclonal antibody strategies and myeloid cell applications, leading to the exploration of astrocytes as a more versatile and abundant resource in the central nervous system.

The engineered CAR constructs incorporate a single-chain variable fragment (scFv) derived from anti-Aβ monoclonal antibodies, paired with intracellular domains from phagocytic receptors. Notably, the designs include constructs that target both soluble and oligomeric Aβ species. The constructs demonstrated robust Aβ-specific phagocytic activity in vitro, highlighting their potential to clear amyloid-beta aggregates effectively. The researchers proceeded to evaluate two specific constructs, Cre-Megf10 and Adu-Dectin1, in the 5xFAD transgenic mouse model, which serves as a preclinical representation of familial Alzheimer’s disease.

This work underscores a pivotal shift in Alzheimer’s research, suggesting that astrocyte-based therapies could provide a one-time, disease-modifying intervention when applied early in the disease process. The implications for drug development are profound, as this approach may streamline the therapeutic timeline and enhance efficacy by targeting the disease at its roots. The findings could catalyze further exploration into astrocytic roles in neurodegeneration, potentially leading to innovative treatments that alter the trajectory of Alzheimer’s disease and improve healthspan outcomes.

Source: nature.com